Cancer stem cell and mesenchymal cell cooperative actions in metastasis progression and hormone resistance in prostate cancer: Potential role of androgen and gonadotropin‑releasing hormone receptors (Review)
- Authors:
- Héctor R. Contreras
- Fernanda López‑Moncada
- Enrique A. Castellón
-
Affiliations: Laboratory of Cellular and Molecular Oncology, Department of Basic and Clinical Oncology, Faculty of Medicine, University of Chile, Santiago 8380453, Chile - Published online on: March 5, 2020 https://doi.org/10.3892/ijo.2020.5008
- Pages: 1075-1082
This article is mentioned in:
Abstract
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA and Jemal A: Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 68:394–424. 2018. View Article : Google Scholar : PubMed/NCBI | |
Rodgers L, Peer CJ and Figg WD: Diagnosis, staging and risk stratification in prostate cancer: Utilizing diagnostic tools to avoid unnecessary therapies and side effects. Cancer Biol Ther. 18:470–472. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shah RB and Zhou M: Recent advances in prostate cancer pathology: Gleason grading and beyond. Pathol Int. 66:260–272. 2016. View Article : Google Scholar : PubMed/NCBI | |
Heijnsdijk EAM, Bangma CH, Borràs JM, de Carvalho TM, Castells X, Eklund M, Espinàs JA, Graefen M, Grönberg H, Lansdorp-Vogelaar I, et al: Summary statement on screening for prostate cancer in Europe. Int J Cancer. 142:741–746. 2018. View Article : Google Scholar | |
Litwin MS and Tan HJ: The diagnosis and treatment of prostate cancer: A review. J Am Med Assoc. 317:2532–2542. 2017. View Article : Google Scholar | |
Ost P, Bossi A, Decaestecker K, De Meerleer G, Giannarini G, Karnes RJ, Roach M III and Briganti A: Metastasis-directed therapy of regional and distant recurrences after curative treatment of prostate cancer: A systematic review of the literature. Eur Urol. 67:852–863. 2015. View Article : Google Scholar | |
Fakhrejahani F, Madan RA and Dahut WL: Management options for biochemically recurrent prostate cancer. Curr Treat Options Oncol. 18:262017. View Article : Google Scholar : PubMed/NCBI | |
Artibani W, Porcaro AB, De Marco V, Cerruto MA and Siracusano S: Management of biochemical recurrence after primary curative treatment for prostate cancer: A review. Urol Int. 100:251–262. 2018. View Article : Google Scholar | |
Sartor O and de Bono JS: Metastatic prostate cancer. N Engl J Med. 378:645–657. 2018. View Article : Google Scholar : PubMed/NCBI | |
Song C, Kang T, Yoo S, Jeong IG, Ro JY, Hong JH, Kim CS and Ahn H: Tumor volume, surgical margin, and the risk of biochemical recurrence in men with organ-confined prostate cancer. Urol Oncol. 31:168–174. 2013. View Article : Google Scholar | |
Suzman DL, Boikos SA and Carducci MA: Bone-targeting agents in prostate cancer. Cancer Metastasis Rev. 33:619–628. 2014. View Article : Google Scholar : PubMed/NCBI | |
Dong L, Zieren RC, Xue W, de Reijke TM and Pienta KJ: Metastatic prostate cancer remains incurable, why? Asian J Urol. 6:26–41. 2019. View Article : Google Scholar : PubMed/NCBI | |
Pelekanou V and Castanas E: Androgen control in prostate cancer. J Cell Biochem. 2234:2224–2234. 2016. View Article : Google Scholar | |
Tan MH, Li J, Xu HE, Melcher K and Yong EL: Androgen receptor: Structure, role in prostate cancer and drug discovery. Acta Pharmacol Sin. 36:3–23. 2014. View Article : Google Scholar : PubMed/NCBI | |
Fujita K and Nonomura N: Role of androgen receptor in prostate cancer: A review. World J Mens Health. 36:288–295. 2018. | |
Rodriguez KM, Pastuszak AW and Khera M: The role of testosterone therapy in the setting of prostate cancer. Curr Urol Rep. 19:672018. View Article : Google Scholar : PubMed/NCBI | |
Obinata D, Takayama K, Takahashi S and Inoue S: Crosstalk of the androgen receptor with transcriptional collaborators: Potential therapeutic targets for castration-resistant prostate cancer. Cancers (Basel). 9:pii: E22. 2017. View Article : Google Scholar | |
Grossmann M, Cheung AS and Zajac JD: Androgens and prostate cancer; pathogenesis and deprivation therapy. Best Pract Res Clin Endocrinol Metab. 27:603–616. 2013. View Article : Google Scholar : PubMed/NCBI | |
Hahn AW, Hale P, Rathi N and Agarwal N: Novel androgen axis systemic therapies for metastatic hormone-sensitive prostate cancer. Curr Opin Urol. 27:559–565. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shore ND, Abrahamsson P, Anderson J, Crawford ED and Lange P: New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 16:7–15. 2013. View Article : Google Scholar | |
Lama G, Papi M, Angelucci C, Maulucci G, Sica G and De Spirito M: Leuprorelin acetate long-lasting effects on GnRH receptors of prostate cancer cells: An atomic force microscopy study of agonist/receptor interaction. PLoS One. 8:e525302013. View Article : Google Scholar : PubMed/NCBI | |
Thomas BC and Neal DE: Androgen deprivation treatment in prostate cancer. BMJ. 346:1–5. 2013. View Article : Google Scholar | |
Katsogiannou M, Ziouziou H, Karaki S, Andrieu C, Henry de Villeneuve M and Rocchi P: The hallmarks of castration-resistant prostate cancers. Cancer Treat Rev. 41:588–597. 2015. View Article : Google Scholar : PubMed/NCBI | |
Yuan X, Cai C, Chen S, Chen S, Yu Z and Balk SP: Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axis. Oncogene. 33:2815–2825. 2014. View Article : Google Scholar | |
Fujimoto N: Role of the androgen-androgen receptor axis in the treatment resistance of advanced prostate cancer: From androgen-dependent to castration resistant and further. J UOEH. 38:129–138. 2016. View Article : Google Scholar : PubMed/NCBI | |
Chandrasekar T, Yang JC, Gao AC and Evans CP: Mechanisms of resistance in castration-resistant prostate cancer (CRPC). Transl Androl Urol. 4:365–380. 2015. | |
Tilki D, Schaeffer EM and Evans CP: Understanding mechanisms of resistance in metastatic castration-resistant prostate cancer: The role of the androgen receptor. Eur Urol Focus. 2:499–505. 2019. View Article : Google Scholar | |
Huang Y, Jiang X, Liang X and Jiang G: Molecular and cellular mechanisms of castration resistant prostate cancer. Oncol Lett. 15:6063–6076. 2018.PubMed/NCBI | |
Ho Y and Dehm SM: Androgen receptor rearrangement and splicing variants in resistance to endocrine therapies in prostate cancer. Endocrinology. 158:1533–1542. 2017. View Article : Google Scholar : PubMed/NCBI | |
Recouvreux MV, Wu JB, Gao AC, Zonis S, Chesnokova V, Bhowmick N, Chung LW and Melmed S: Androgen receptor regulation of local growth hormone in prostate cancer cells. Endocrinology. 158:2255–2568. 2017. View Article : Google Scholar : PubMed/NCBI | |
Stelloo S, Nevedomskaya E, van der Poel HG, de Jong J, van Leenders GJ, Jenster G, Wessels LF, Bergman AM and Zwart W: Androgen receptor profiling predicts prostate cancer outcome. EMBO Mol Med. 7:1450–1464. 2015. View Article : Google Scholar : PubMed/NCBI | |
Höti N, Shah P, Hu Y, Yang S and Zhang H: Proteomics analyses of prostate cancer cells reveal cellular pathways associated with androgen resistance. Proteomics. 17:2017. View Article : Google Scholar : PubMed/NCBI | |
Van Den Eeden SK, Lu R, Zhang N, Quesenberry CP Jr, Shan J, Han JS, Tsiatis AC, Leimpeter AD, Lawrence HJ, Febbo PG and Presti JC: A Biopsy-based 17-gene genomic prostate score as a predictor of metastases and prostate cancer death in surgically treated men with clinically localized disease. Eur Urol. 73:129–138. 2017. View Article : Google Scholar : PubMed/NCBI | |
Hanahan D and Weinberg RA: Hallmarks of cancer: The next generation. Cell. 144:646–674. 2011. View Article : Google Scholar : PubMed/NCBI | |
Nieto MA, Huang RY, Jackson RA and Thiery JP: EMT: 2016. Cell. 166:21–45. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hasegawa S, Nagano H, Konno M, Eguchi H, Tomokuni A, Tomimaru Y, Asaoka T, Wada H, Hama N, Kawamoto K, et al: A crucial epithelial to mesenchymal transition regulator, Sox4/Ezh2 axis is closely related to the clinical outcome in pancreatic cancer patients. Int J Oncol. 48:145–152. 2016. View Article : Google Scholar | |
Frisch SM, Schaller M and Cieply B: Mechanisms that link the oncogenic epithelial-mesenchymal transition to suppression of anoikis. J Cell Sci. 126:21–29. 2013. View Article : Google Scholar : PubMed/NCBI | |
Serrano-Gomez SJ, Maziveyi M and Alahari SK: Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications. Mol Cancer. 15:182016. View Article : Google Scholar : PubMed/NCBI | |
Mateo F, Meca-Cortés O, Celià-Terrassa T, Fernández Y, Abasolo I, Sánchez-Cid L, Bermudo R, Sagasta A, Rodríguez-Carunchio L, Pons M, et al: SPARC mediates metastatic cooperation between CSC and non-CSC prostate cancer cell subpopulations. Mol Cancer. 13:2372014. View Article : Google Scholar : PubMed/NCBI | |
Lin KC, Torga G, Sun Y, Axelrod R, Pienta KJ, Sturm JC and Austin RH: The role of heterogeneous environment and docetaxel gradient in the emergence of polyploid, mesenchymal and resistant prostate cancer cells. Clin Exp Metastasis. 36:97–108. 2019. View Article : Google Scholar : PubMed/NCBI | |
Bakker B, Taudt A, Belderbos ME, Porubsky D, Spierings DC, de Jong TV, Halsema N, Kazemier HG, Hoekstra-Wakker K, Bradley A, et al: Single-cell sequencing reveals karyotype heterogeneity in murine and human malignancies. Genome Biol. 17:1152016. View Article : Google Scholar : PubMed/NCBI | |
Chapman MP, Risom T, Aswani AJ, Langer EM, Sears RC and Tomlin CJ: Modeling differentiation-state transitions linked to therapeutic escape in triple-negative breast cancer. PLoS Comput Biol. 15:e10068402019. View Article : Google Scholar : PubMed/NCBI | |
Eun K, Ham SW and Kim H: Cancer stem cell heterogeneity: Origin and new perspectives on CSC targeting. BMB Rep. 50:117–125. 2017. View Article : Google Scholar : | |
Adamowicz J, Pakravan K, Bakhshinejad B, Drewa T and Babashah S: Prostate cancer stem cells: From theory to practice. Scand J Urol. 51:95–106. 2017. View Article : Google Scholar : PubMed/NCBI | |
Shahriari K, Shen F, Worrede-Mahdi A, Liu Q, Gong Y, Garcia FU and Fatatis A: Cooperation among heterogeneous prostate cancer cells in the bone metastatic niche. Oncogene. 36:2846–2856. 2017. View Article : Google Scholar : | |
Chang L, Graham P, Hao J, Ni J, Deng J, Bucci J, Malouf D, Gillatt D and Li Y: Cancer stem cells and signaling pathways in radioresistance. Oncotarget. 7:11002–11017. 2016. | |
Geng SQ, Alexandrou AT and Li JJ: Breast cancer stem cells: Multiple capacities in tumor metastasis. Cancer Lett. 349:1–7. 2014. View Article : Google Scholar : PubMed/NCBI | |
Leão R, Domingos C, Figueiredo A, Hamilton R, Tabori U and Castelo-Branco P: Cancer stem cells in prostate cancer: Implications for targeted therapy. Urol Int. 99:125–136. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rosario DJ, Davey P, Green J, Greene D, Turner B, Payne H and Kirby M: The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK. World J Urol. 34:1601–1609. 2016. View Article : Google Scholar : PubMed/NCBI | |
Poelaert F, Kumps C, Lumen N, Verschuere S, Libbrecht L, Praet M, Rottey S, Claeys T, Ost P, Decaestecker K, et al: Androgen receptor gene copy number and protein expression in treatment-naïve prostate cancer. Urol Int. 99:222–228. 2017. View Article : Google Scholar | |
Prekovic S, van Royen ME, Voet AR, Geverts B, Houtman R, Melchers D, Zhang KY, Van den Broeck T, Smeets E, Spans L, et al: The effect of F877L and T878A mutations on androgen receptor response to enzalutamide. Mol Cancer Ther. 15:1702–1712. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sutinen P, Malinen M, Heikkinen S and Palvimo JJ: SUMOylation modulates the transcriptional activity of androgen receptor in a target gene and pathway selective manner. Nucleic Acids Res. 42:8310–8319. 2014. View Article : Google Scholar : PubMed/NCBI | |
Rowlands MA, Holly JM, Hamdy F, Phillips J, Goodwin L, Marsden G, Gunnell D, Donovan J, Neal DE and Martin RM: Serum insulin-like growth factors and mortality in localised and advanced clinically detected prostate cancer. Cancer Causes Control. 23:347–354. 2012. View Article : Google Scholar | |
Lescarbeau RM, Seib FP, Prewitz M, Werner C and Kaplan DL: In vitro model of metastasis to bone marrow mediates prostate cancer castration resistant growth through paracrine and extracellular matrix factors. PLoS One. 7:e403722012. View Article : Google Scholar : PubMed/NCBI | |
Penning TM and Tamae D: Current advances in intratumoral androgen metabolism in castration-resistant prostate cancer. Curr Opin Endocrinol Diabetes Obes. 23:264–270. 2016. View Article : Google Scholar : PubMed/NCBI | |
Price DK, Chau CH, Till C, Goodman PJ, Leach RJ, Johnson-Pais TL, Hsing AW, Hoque A, Parnes HL, Schenk JM, et al: Association of androgen metabolism gene polymorphisms with prostate cancer risk and androgen concentrations: Results from the prostate cancer prevention trial. Cancer. 122:2332–2340. 2016. View Article : Google Scholar : PubMed/NCBI | |
Clementi M, Sánchez C, Benitez DA, Contreras HR, Huidobro C, Cabezas J, Acevedo C and Castellón EA: Gonadotropin releasing hormone analogs induce apoptosis by extrinsic pathway involving p53 phosphorylation in primary cell cultures of human prostatic adenocarcinomas. Prostate. 69:1025–1033. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sánchez C, Clementi M, Benitez D, Contreras H, Huidobro C and Castellón E: Effect of GnRH analogs on the expression of TrkA and p75 neurotrophin receptors in primary cell cultures from human prostate adenocarcinoma. Prostate. 65:195–202. 2005. View Article : Google Scholar : PubMed/NCBI | |
Angelucci C, Lama G, Iacopino F, Ferracuti S, Bono AV, Millar RP and Sica G: GnRH receptor expression in human prostate cancer cells is affected by hormones and growth factors. Endocrine. 36:87–97. 2009. View Article : Google Scholar : PubMed/NCBI | |
Sánchez CA, Mercado AJ, Contreras HR, Cabezas JC, Huidobro CC and Castellón EA: Pharmacoperone IN3 enhances the apoptotic effect of leuprolide in prostate cancer cells by increasing the gonadotropin-releasing hormone receptor in the cell membrane. Anticancer Drugs. 23:959–969. 2012.PubMed/NCBI | |
Castellón E, Clementi M, Hitschfeld C, Sánchez C, Benítez D, Sáenz L, Contreras H and Huidobro C: Effect of leuprolide and cetrorelix on cell growth, apoptosis, and GnRH receptor expression in primary cell cultures from human prostate carcinoma. Cancer Invest. 24:261–268. 2006. View Article : Google Scholar : PubMed/NCBI | |
Saltzstein D, Shore ND, Moul JW, Chu F, Concepcion R, de la Motte S, McLane JA, Atkinson S, Yang A and Crawford ED: Pharmacokinetic and pharmacodynamic comparison of subcutaneous versus intramuscular leuprolide acetate formulations in male subjects. Ther Adv Urol. 10:43–50. 2017. View Article : Google Scholar | |
Nieto MA and Cano A: The epithelial-mesenchymal transition under control: Global programs to regulate epithelial plasticity. Semin Cancer Biol. 22:361–368. 2012. View Article : Google Scholar : PubMed/NCBI | |
García de Herreros A and Baulida J: Cooperation, amplification, and feed-back in epithelial-mesenchymal transition. Biochim Biophys Acta. 1825:223–228. 2012.PubMed/NCBI | |
Savagner P: The epithelial-mesenchymal transition (EMT) phenomenon. Ann Oncol. 21(Suppl 7): vii89–vii92. 2010. View Article : Google Scholar : PubMed/NCBI | |
Chen T, You Y, Jiang H and Wang ZZ: Epithelial-mesenchymal transition (EMT): A biological process in the development, stem cell differentiation, and tumorigenesis. J Cell Physiol. 232:3261–3272. 2017. View Article : Google Scholar : PubMed/NCBI | |
Micalizzi DS, Farabaugh SM and Ford HL: Epithelial- mesen-chymal transition in cancer: Parallels between normal development and tumor progression. J Mammary Gland Biol Neoplasia. 15:117–134. 2010. View Article : Google Scholar : PubMed/NCBI | |
De Craene B and Berx G: Regulatory networks defining EMT during cancer initiation and progression. Nat Rev Cancer. 13:97–110. 2013. View Article : Google Scholar : PubMed/NCBI | |
Osorio LA, Farfán NM, Castellón EA and Contreras HR: SNAIL transcription factor increases the motility and invasive capacity of prostate cancer cells. Mol Med Rep. 13:778–786. 2016. View Article : Google Scholar : | |
Orellana-Serradell O, Herrera D, Castellón EA and Contreras HR: The transcription factor ZEB1 promotes an aggressive phenotype in prostate cancer cell lines. Asian J Androl. 20:294–299. 2018. View Article : Google Scholar : | |
Contreras HR, Ledezma RA, Vergara J, Cifuentes F, Barra C, Cabello P, Gallegos I, Morales B, Huidobro C and Castellón EA: The expression of syndecan-1 and -2 is associated with Gleason score and epithelial-mesenchymal transition markers, E-cadherin and beta-catenin, in prostate cancer. Urol Oncol. 28:534–540. 2010. View Article : Google Scholar | |
Poblete CE, Fulla J, Gallardo M, Muñoz V, Castellón EA, Gallegos I and Contreras HR: Increased SNAIL expression and low syndecan levels are associated with high Gleason grade in prostate cancer. Int J Oncol. 44:647–654. 2014. View Article : Google Scholar : PubMed/NCBI | |
Farfán N, Ocarez N, Castellón EA, Mejía N, de Herreros AG and Contreras HR: The transcriptional factor ZEB1 represses Syndecan 1 expression in prostate cancer. Sci Rep. 8:114672018. View Article : Google Scholar : PubMed/NCBI | |
Montanari M, Rossetti S, Cavaliere C, D'Aniello C, Malzone MG, Vanacore D, Di Franco R, La Mantia E, Iovane G, Piscitelli R, et al: Epithelial-mesenchymal transition in prostate cancer: An overview. Oncotarget. 8:35376–35389. 2017. View Article : Google Scholar : PubMed/NCBI | |
Mitra A, Mishra L and Li S: EMT, CTCs and CSCs in tumor relapse and drug-resistance. Oncotarget. 6:10699–10710. 2015. View Article : Google Scholar | |
Peitzsch C, Tyutyunnykova A, Pantel K and Dubrovska A: Cancer stem cells: The root of tumor recurrence and metastases. Semin Cancer Biol. 44:10–24. 2017. View Article : Google Scholar : PubMed/NCBI | |
Ajani JA, Song S, Hochster HS and Steinberg IB: Cancer stem cells: The promise and the potential. Semin Oncol. 42(Suppl 1): S3–S17. 2015. View Article : Google Scholar : PubMed/NCBI | |
Castellón EA, Valenzuela R, Lillo J, Castillo V, Contreras HR, Gallegos I, Mercado A and Huidobro C: Molecular signature of cancer stem cells isolated from prostate carcinoma and expression of stem markers in different Gleason grades and metastasis. Biol Res. 45:297–305. 2012. View Article : Google Scholar | |
Castillo V, Valenzuela R, Huidobro C, Contreras HR and Castellon EA: Functional characteristics of cancer stem cells and their role in drug resistance of prostate cancer. Int J Oncol. 45:985–994. 2014. View Article : Google Scholar : PubMed/NCBI | |
McGranahan N and Swanton C: Clonal heterogeneity and tumor evolution: Past, present, and the future. Cell. 168:613–628. 2017. View Article : Google Scholar : PubMed/NCBI | |
Bosman FT: Tumor heterogeneity: Will it change what pathologists do. Pathobiology. 85:18–22. 2018. View Article : Google Scholar | |
Jolly MK and Celià-Terrassa T: Dynamics of phenotypic heterogeneity during EMT and stemness in cancer progression. J Clin Med. 8:pii: E1542. 2019. View Article : Google Scholar | |
Bu Y and Cao D: The origin of cancer stem cells. Front Biosci (Schol Ed). 4:819–830. 2012. | |
Parsons BL: Multiclonal tumor origin: Evidence and implications. Mutat Res. 777:1–18. 2018. View Article : Google Scholar : PubMed/NCBI | |
Vicente-Dueñas C, Hauer J, Cobaleda C, Borkhardt A and Sánchez-García I: Epigenetic priming in cancer initiation. Trends Cancer. 4:408–417. 2018. View Article : Google Scholar : PubMed/NCBI | |
Ye X and Weinberg RA: Epithelial-mesenchymal plasticity: A central regulator of cancer progression. Trends Cell Biol. 25:675–686. 2015. View Article : Google Scholar : PubMed/NCBI | |
Graham TA and Sottoriva A: Measuring cancer evolution from the genome. J Pathol. 241:183–191. 2017. View Article : Google Scholar | |
Francart M, Lambert J, Vanwynsberghe AM, Thompson EW, Bourcy M, Polette M and Gilles C: Epithelial-mesenchymal plasticity and circulating tumor cells: Travel companions to metastases. Dev Dyn. 247:432–450. 2018. View Article : Google Scholar | |
Carnero A and Lleonart M: The hypoxic microenvironment: A determinant of cancer stem cell evolution. Bioessays. 38(Suppl 1): S65–S74. 2016. View Article : Google Scholar : PubMed/NCBI | |
Yeo CD, Kang N, Choi SY, Kim BN, Park CK, Kim JW, Kim YK and Kim SJ: The role of hypoxia on the acquisition of epithelial-mesenchymal transition and cancer stemness: A possible link to epigenetic regulation. Korean J Intern Med. 32:589–599. 2017. View Article : Google Scholar : PubMed/NCBI | |
Rhim AD: Epithelial to mesenchymal transition and the generation of stem-like cells in pancreatic cancer. Pancreatology. 13:114–117. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lan L, Luo Y, Cui D, Shi BY, Deng W, Huo LL, Chen HL, Zhang GY and Deng LL: Epithelial-mesenchymal transition triggers cancer stem cell generation in human thyroid cancer cells. Int J Oncol. 43:113–120. 2013. View Article : Google Scholar : PubMed/NCBI | |
Li N, Babaei-Jadidi R, Lorenzi F, Spencer-Dene B, Clarke P, Domingo E, Tulchinsky E, Vries RGJ, Kerr D, Pan Y, et al: An FBXW7-ZEB2 axis links EMT and tumour microenvironment to promote colorectal cancer stem cells and chemoresistance. Oncogenesis. 8:132019. View Article : Google Scholar : PubMed/NCBI | |
Croker AK and Allan AL: Cancer stem cells: Implications for the progression and treatment of metastatic disease. J Cell Mol Med. 12:374–390. 2008. View Article : Google Scholar : PubMed/NCBI | |
Massagué J and Obenauf AC: Metastatic colonization by circulating tumour cells. Nature. 529:298–306. 2016. View Article : Google Scholar : PubMed/NCBI | |
Hayashida T, Jinno H, Kitagawa Y and Kitajima M: Cooperation of cancer stem cell properties and epithelial-mesenchymal transition in the establishment of breast cancer metastasis. J Oncol. 2011:5914272011. View Article : Google Scholar : PubMed/NCBI | |
Hsu CL, Chung FH, Chen CH, Hsu TT, Liu SM, Chung DS, Hsu YF, Chen CL, Ma N and Lee HC: Genotypes of cancer stem cells characterized by epithelial-to-mesenchymal transition and proliferation related functions. Sci Rep. 6:325232016. View Article : Google Scholar : PubMed/NCBI | |
Yun EJ, Lo UG and Hsieh JT: The evolving landscape of prostate cancer stem cell: Therapeutic implications and future challenges. Asian J Urol. 3:203–210. 2016. View Article : Google Scholar : PubMed/NCBI | |
Lin CJ, Lo UG and Hsieh JT: The regulatory pathways leading to stem-like cells underlie prostate cancer progression. Asian J Androl. 21:233–240. 2019. View Article : Google Scholar : | |
Sánchez CA, Andahur EI, Valenzuela R, Castellón EA, Fullá JA, Ramos CG and Triviño JC: Exosomes from bulk and stem cells from human prostate cancer have a differential microRNA content that contributes cooperatively over local and pre-metastatic niche. Oncotarget. 7:3993–4008. 2016. View Article : Google Scholar : | |
Hoshino A, Costa-Silva B, Shen TL, Rodrigues G, Hashimoto A, Tesic Mark M, Molina H, Kohsaka S, Di Giannatale A, Ceder S, et al: Tumour exosome integrins determine organo-tropic metastasis. Nature. 527:329–335. 2015. View Article : Google Scholar : PubMed/NCBI | |
Langley RR and Fidler IJ: The seed and soil hypothesis revisited-The role of tumor-stroma interactions in metastasis to different organs. Int J Cancer. 128:2527–2535. 2011. View Article : Google Scholar : PubMed/NCBI | |
Miftakhova R, Hedblom A, Semenas J, Robinson B, Simoulis A, Malm J, Rizvanov A, Heery DM, Mongan NP, Maitland NJ, et al: Cyclin A1 and P450 aromatase promote metastatic homing and growth of stem-like prostate cancer cells in the bone marrow. Cancer Res. 76:2453–2464. 2016. View Article : Google Scholar : PubMed/NCBI | |
Shiozawa Y, Berry JE, Eber MR, Jung Y, Yumoto K, Cackowski FC, Yoon HJ, Parsana P, Mehra R, Wang J, et al: The marrow niche controls the cancer stem cell phenotype of disseminated prostate cancer. Oncotarget. 7:41217–41232. 2016. View Article : Google Scholar : PubMed/NCBI | |
Sharma S, Xing F, Liu Y, Wu K, Said N, Pochampally R, Shiozawa Y, Lin HK, Balaji KC and Watabe K: Secreted protein acidic and rich in cysteine (SPARC) mediates metastatic dormancy of prostate cancer in the bone. J Biol Chem. 291:19351–19363. 2016. View Article : Google Scholar : PubMed/NCBI | |
Jin J, Dayyani F and Gallick G: Steps in prostate cancer progression that lead to bone metastasis. Int J Cancer. 128:2545–2561. 2011. View Article : Google Scholar : PubMed/NCBI | |
Peyruchaud O, Leblanc R and David M: Pleiotropic activity of lysophosphatidic acid in bone metastasis. Biochim Biophys Acta. 1831:99–104. 2013. View Article : Google Scholar | |
Roodman GD: Genes associate with abnormal bone cell activity in bone metastasis. Cancer Metastasis Rev. 31:569–578. 2012. View Article : Google Scholar : PubMed/NCBI | |
Zhang T and Armstrong AJ: Clinical utility of circulating tumor cells in advanced prostate cancer. Curr Oncol Rep. 18:32016. View Article : Google Scholar | |
Barriere G, Fici P, Gallerani G, Fabbri F, Zoli W and Rigaud M: Circulating tumor cells and epithelial, mesenchymal and stemness markers: Characterization of cell subpopulations. Ann Transl Med. 2:1092014.PubMed/NCBI | |
Vogelzang NJ, Fizazi K, Burke JM, De Wit R, Bellmunt J, Hutson TE, Crane E, Berry WR, Doner K, Hainsworth JD, et al: Circulating tumor cells in a phase 3 study of docetaxel and prednisone with or without lenalidomide in metastatic Castration-resistant prostate cancer. Eur Urol. 71:168–171. 2017. View Article : Google Scholar | |
Srivatsa N, Nagaraja H, Shweta S and Raghunath S: Radical prostatectomy for locally advanced prostate cancers-review of literature. Indian J Surg Oncol. 8:175–180. 2017. View Article : Google Scholar : PubMed/NCBI | |
Wilt T, Brawe M, Jones K, Barry MJ, Aronson WJ, Fox S, Gingrich JR, Wei JT, Gilhooly P, Grob BM, et al: Radical prostatectomy versus observation for localized prostate cancer. N Engl J Med. 367:203–213. 2012. View Article : Google Scholar : PubMed/NCBI | |
Celià-Terrassa T, Meca-Cortés Ó, Mateo F, Martínez de Paz A, Rubio N, Arnal-Estapé A, Ell BJ, Bermudo R, Díaz A, Guerra-Rebollo M, et al: Epithelial-mesenchymal transition can suppress major attributes of human epithelial tumor-initiating cells. J Clin Invest. 122:1846–1868. 2012. View Article : Google Scholar | |
López-Moncada F, Torres MJ, Castellón EA and Contreras HR: Secreted protein acidic and rich in cysteine (SPARC) induces epithelial-mesenchymal transition, enhancing migration and invasion, and is associated with high Gleason score in prostate cancer. Asian J Androl. 21:557–564. 2019. View Article : Google Scholar : PubMed/NCBI | |
Gunasinghe NP, Wells A, Thompson EW and Hugo HJ: Mesenchymal-epithelial transition (MET) as a mechanism for metastatic colonisation in breast cancer. Cancer Metastasis Rev. 31:469–478. 2012. View Article : Google Scholar : PubMed/NCBI | |
Bullock MD, Sayan AE, Packham GK and Mirnezami AH: MicroRNAs: Critical regulators of epithelial to mesenchymal (EMT) and mesenchymal to epithelial transition (MET) in cancer progression. Biol Cell. 104:3–12. 2012. View Article : Google Scholar | |
Bocci F, Gearhart-Serna L, Boareto M, Ribeiro M, Ben-Jacob E, Devi GR, Levine H, Onuchic JN and Jolly MK: Toward understanding cancer stem cell heterogeneity in the tumor microenvironment. Proc Natl Acad Sci USA. 116:148–157. 2019. View Article : Google Scholar | |
Harris JE, Shin J, Lee B, Pelosky K, Hooker CM, Harbom K, Hulbert A, Zahnow C, Yang SC, Baylin S, et al: A murine xenograft model of spontaneous metastases of human lung adenocarcinoma. J Surg Res. 171:e75–e79. 2011. View Article : Google Scholar : PubMed/NCBI | |
Rea D, Del Vecchio V, Palma G, Barbieri A, Falco M, Luciano A, De Biase D, Perdonà S, Facchini G and Arra C: Mouse models in prostate cancer translational research: From Xenograft to PDX. Biomed Res Int. 2016:112016. View Article : Google Scholar | |
Daphu I, Sundstrøm T, Horn S, Huszthy PC, Niclou SP, Sakariassen PØ, Immervoll H, Miletic H, Bjerkvig R and Thorsen F: In vivo animal models for studying brain metastasis: Value and limitations. Clin Exp Metastasis. 30:695–610. 2013. View Article : Google Scholar : PubMed/NCBI | |
Romano G, Chagani S and Kwong LN: The path to metastatic mouse models of colorectal cancer. Oncogene. 37:2481–2489. 2018. View Article : Google Scholar : PubMed/NCBI | |
Kahn J, Tofilon PJ and Camphausen K: Preclinical models in radiation oncology. Radiat Oncol. 7:2232012. View Article : Google Scholar : PubMed/NCBI | |
Loi M, Di Paolo D, Becherini P, Zorzoli A, Perri P, Carosio R, Cilli M, Ribatti D, Brignole C, Pagnan G, et al: The use of orthotopic models to validate antivascular therapies for cancer. Int J Dev Biol. 55:547–555. 2011. View Article : Google Scholar | |
Grabowska MM, Degraff DJ, Yu X, Jin RJ, Chen Z, Borowsky AD and Matusik RJ: Mouse models of prostate cancer: Picking the best model for the question. Cancer Metastasis Rev. 33:377–397. 2014. View Article : Google Scholar : PubMed/NCBI | |
Usary J, Zhao W, Darr D, Roberts PJ, Liu M, Balletta L, Karginova O, Jordan J, Combest A, Bridges A, et al: Predicting drug responsiveness in human cancers using genetically engineered mice. Clin Cancer Res. 19:4889–4899. 2013. View Article : Google Scholar : PubMed/NCBI | |
Bastide C, Bagnis C, Mannoni P, Hassoun J and Bladou F: A Nod Scid mouse model to study human prostate cancer. Prostate Cancer Prostatic Dis. 5:311–315. 2002. View Article : Google Scholar | |
Hidalgo M, Amant F, Biankin AV, Budinská E, Byrne AT, Caldas C, Clarke RB, de Jong S, Jonkers J, Mælandsmo GM, et al: Patient derived xenograft models: An emerging platform for translational cancer research. Cancer Discov. 4:998–1013. 2014. View Article : Google Scholar : PubMed/NCBI | |
Dai J, Hensel J, Wang N, Kruithof-de Julio M and Shiozawa Y: Mouse models for studying prostate cancer bone metastasis. Bonekey Rep. 5:7772016. View Article : Google Scholar : PubMed/NCBI | |
Tumati V, Mathur S, Song K, Hsieh JT, Zhao D, Takahashi M, Dobin T, Gandee L, Solberg TD, Habib AA and Saha D: Development of a locally advanced orthotopic prostate tumor model in rats for assessment of combined modality therapy. Int J Oncol. 42:1613–1619. 2013. View Article : Google Scholar : PubMed/NCBI | |
Lee ST, Wong PF, He H, Hooper JD and Mustafa MR: Alpha-tomatine attenuation of in vivo growth of subcutaneous and orthotopic xenograft tumors of human prostate carcinoma PC-3 cells is accompanied by inactivation of nuclear factor-Kappa B signaling. PLoS One. 8:e577082013. View Article : Google Scholar : PubMed/NCBI | |
Wang Y, Xue H, Cutz JC, Bayani J, Mawji NR, Chen WG, Goetz LJ, Hayward SW, Sadar MD, Gilks CB, et al: An orthotopic metastatic prostate cancer model in SCID mice via grafting of a transplantable human prostate tumor line. Lab Invest. 85:1392–1404. 2005. View Article : Google Scholar : PubMed/NCBI | |
Cifuentes FF, Valenzuela RH, Contreras HR and Castellón EA: Development of an orthotopic model of human metastatic prostate cancer in the NOD-SCIDγ mouse (Mus musculus) anterior prostate. Oncol Lett. 10:2142–2148. 2015. View Article : Google Scholar : PubMed/NCBI | |
Cifuentes FF, Valenzuela RH, Contreras HR and Castellón EA: Surgical cytoreduction of the primary tumor reduces metastatic progression in a mouse model of prostate cancer. Oncol Rep. 34:2837–2844. 2015. View Article : Google Scholar : PubMed/NCBI |